Latest Insider Transactions at Artivion, Inc. (AORT)
This section provides a real-time view of insider transactions for Artivion, Inc. (AORT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARTIVION, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARTIVION, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 23
2021
|
Dennis B Maier SVP, Operations |
SELL
Open market or private sale
|
Direct |
2,715
-13.31%
|
$67,875
$25.64 P/Share
|
Jun 01
2021
|
Thomas F Ackerman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+3.56%
|
$128,267
$29.39 P/Share
|
Jun 01
2021
|
Daniel J Bevevino Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+3.56%
|
$128,267
$29.39 P/Share
|
Jun 01
2021
|
Marna P Borgstrom Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+18.97%
|
$128,267
$29.39 P/Share
|
Jun 01
2021
|
James Bullock Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+10.32%
|
$128,267
$29.39 P/Share
|
Jun 01
2021
|
Jeffrey H Burbank Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+15.79%
|
$128,267
$29.39 P/Share
|
Jun 01
2021
|
Ronald D Mc Call Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+3.35%
|
$128,267
$29.39 P/Share
|
Jun 01
2021
|
Harvey Morgan Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+7.52%
|
$128,267
$29.39 P/Share
|
Jun 01
2021
|
Jon W Salveson Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,423
+4.25%
|
$128,267
$29.39 P/Share
|
May 25
2021
|
Ronald D Mc Call Director |
SELL
Open market or private sale
|
Direct |
5,783
-4.49%
|
$167,707
$29.55 P/Share
|
May 25
2021
|
John E Davis Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,402
+6.0%
|
$140,452
$26.24 P/Share
|
May 25
2021
|
John E Davis Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,739
-5.24%
|
$369,431
$29.67 P/Share
|
May 06
2021
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
6,618
-7.05%
|
$198,540
$30.5 P/Share
|
May 06
2021
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
6,618
+6.59%
|
$66,180
$10.24 P/Share
|
May 06
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,731
-6.03%
|
$171,930
$30.0 P/Share
|
May 06
2021
|
Amy Horton VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,731
+5.69%
|
$63,041
$11.0 P/Share
|
May 05
2021
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
6,618
-7.05%
|
$191,922
$29.5 P/Share
|
May 05
2021
|
Jean F Holloway SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
6,618
+6.59%
|
$66,180
$10.24 P/Share
|
May 05
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,186
-5.49%
|
$155,580
$30.0 P/Share
|
May 05
2021
|
Amy Horton VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,186
+5.2%
|
$57,046
$11.0 P/Share
|
May 05
2021
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Open market or private sale
|
Direct |
27,242
-8.52%
|
$817,260
$30.0 P/Share
|
May 05
2021
|
David Ashley Lee Executive VP, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,242
+7.85%
|
$299,662
$11.0 P/Share
|
Apr 30
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,700
-2.94%
|
$81,000
$30.0 P/Share
|
Apr 30
2021
|
Amy Horton VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,700
+2.85%
|
$29,700
$11.0 P/Share
|
Apr 30
2021
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Open market or private sale
|
Direct |
6,800
-2.27%
|
$204,000
$30.0 P/Share
|
Apr 30
2021
|
David Ashley Lee Executive VP, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,800
+2.22%
|
$74,800
$11.0 P/Share
|
Apr 30
2021
|
James P Mackin President & CEO |
SELL
Open market or private sale
|
Direct |
45,734
-6.95%
|
$1,280,552
$28.0 P/Share
|
Apr 30
2021
|
James P Mackin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
45,734
+6.47%
|
$457,340
$10.18 P/Share
|
Apr 30
2021
|
Dennis B Maier SVP, Operations |
SELL
Open market or private sale
|
Direct |
3,861
-8.3%
|
$108,108
$28.0 P/Share
|
Apr 30
2021
|
Dennis B Maier SVP, Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
3,314
+12.27%
|
$69,594
$21.55 P/Share
|
Mar 16
2021
|
Marshall S. Stanton SVP, Clinical & MD Affair |
BUY
Grant, award, or other acquisition
|
Direct |
8,511
+47.23%
|
-
|
Mar 12
2021
|
Scott B Capps VP, Clinical Research |
SELL
Payment of exercise price or tax liability
|
Direct |
1,393
-0.45%
|
$34,825
$25.05 P/Share
|
Mar 12
2021
|
John E Davis Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,236
-1.38%
|
$55,900
$25.05 P/Share
|
Mar 12
2021
|
Jean F Holloway SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,682
-1.5%
|
$67,050
$25.05 P/Share
|
Mar 12
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,739
-0.96%
|
$43,475
$25.05 P/Share
|
Mar 12
2021
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,074
-0.52%
|
$76,850
$25.05 P/Share
|
Mar 12
2021
|
James P Mackin President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,766
-2.48%
|
$394,150
$25.05 P/Share
|
Mar 12
2021
|
Dennis B Maier SVP, Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,385
-3.13%
|
$34,625
$25.05 P/Share
|
Mar 10
2021
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,693
-1.85%
|
$42,325
$25.28 P/Share
|
Mar 08
2021
|
Franz Peter Barthold VP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
76
-0.62%
|
$1,824
$24.3 P/Share
|
Mar 05
2021
|
Franz Peter Barthold VP, Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
103
-0.84%
|
$2,472
$24.44 P/Share
|
Mar 05
2021
|
Scott B Capps VP, Clinical Research |
SELL
Payment of exercise price or tax liability
|
Direct |
205
-0.13%
|
$4,920
$24.44 P/Share
|
Mar 05
2021
|
John E Davis Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
315
-0.39%
|
$7,560
$24.44 P/Share
|
Mar 05
2021
|
Jean F Holloway SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
299
-0.33%
|
$7,176
$24.44 P/Share
|
Mar 05
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
226
-0.25%
|
$5,424
$24.44 P/Share
|
Mar 05
2021
|
David Ashley Lee Executive VP, COO & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
359
-0.12%
|
$8,616
$24.44 P/Share
|
Mar 05
2021
|
James P Mackin President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,487
-0.46%
|
$35,688
$24.44 P/Share
|
Mar 05
2021
|
Dennis B Maier SVP, Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
205
-0.91%
|
$4,920
$24.44 P/Share
|
Mar 05
2021
|
Michael S Simpson SVP, Regulatory Affairs and QA |
SELL
Payment of exercise price or tax liability
|
Direct |
304
-0.89%
|
$7,296
$24.44 P/Share
|
Mar 01
2021
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
13,619
-12.99%
|
$340,475
$25.53 P/Share
|